Internet Archive's in-browser audio player requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see your browser settings for this feature.

RT-MB_Covid-19_Related

by: ok33

Publication date: 2020-03-31

Usage: Public Domain Mark 1.0

Language: English

Most of the sound frequencies used in these recordings
correspond either to the molar mass or equivalent scalar
octave of the related products.

This work is dedicated to the public domain and

may be reproduced without authorization.

* Note: Download here the ZIP file with THE GUIDE, a freeware tree-based information management tool for Windows featuring ALL the content related to resonant-therapy. Download, extract the ZIP and open the executable Resonant Therapy file inside. Alternatively, download here the other ZIP file with the platform independent freeware Knowledge Base program ALEX PKB with the content included. Download, extract the ZIP and open the executable JAR file. (Visit location)

Algorithmic piano music mixed with sound frequencies.

Public Domain

* Arginase Inhibitors Mix. Arginine is an amino acid that has been shown in nonclinical studies to be essential in the life cycle of many viruses. Therefore, arginine depletion may be an effective therapeutic approach against SARS-CoV-2. In addition to the putative direct antiviral activity with regard to SARS-COV-2, arginine depletion may also attenuate the pulmonary inflammation seen in COVID-19. Severe cases of COVID-19 are characterized by a hyperinflammatory lung pathology and local tissue damage that contribute to poor patient outcome. Several arginine-metabolizing enzymes in clinical development may be a viable approach to induce a low arginine environment to treat COVID-19 and other viral diseases produced by the families Herpesviridae and Adenoviridae. In tumor biology and medicinal chemistry arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the tumor microenvironment and preventing the immune system’s cytotoxic T-cells and natural killer (NK) cells from proliferating and killing the tumor. Inhibition of arginase activity reverses this immunosuppressive block and restores T-cell function. Arginase contributes to atherosclerosis and microvascular endothelial dysfunction in obesity. Its impact is reduced by aging because of higher levels of vascular oxidative stress. Obesity is accompanied by accelerated microvascular remodeling, the extent of which is related to the amount of arginase in the vascular wall. Small-molecule arginase inhibitors are currently described as promising therapeutic agents for the treatment of variety of diseases, including diseases associated with pathogens, ulcerative colitis, inflammatory bowel disease, allergic asthma, cardiovascular diseases, immune disorders, and cancer. The recording plays simultaneously the sound frequencies of Arginase Inhibitor 1, CB-1158-analog, CB-1158 (dihydrochloride), and 2(S)-amino-6-boronohexanoic acid (ABH). WARNING: Do not play this in the vicinity of either cats or kittens.
( https://doi.org/10.1016/j.ijid.2020.10.100 )

* Camostat-K11777. The transmembrane serine protease, TMPRSS2 is an important target in the treatment of seasonal influenza infections and contributes to prostate carcinogenesis and metastasis. TMPRSS2 inhibition is also used in the treatment of some forms of cancer and is effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis. Recent research has found that Camostat inhibition of TMPRSS2 partially blocked infection by SARS-CoV and Human coronavirus NL63 in HeLa cells. Another in vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19. Viral spread and pathogenesis of SARS-CoV is driven by serine rather than cysteine proteases and can be effectively prevented by Camostat. Camostat has been clinically used to treat chronic pancreatitis, and thus represents an exciting potential therapeutic for respiratory coronavirus infections. Camostat, or similar serine protease inhibitors, might be an effective option for treatment of SARS and potentially MERS, while vinyl sulfone-based inhibitors are excellent lead candidates for Ebola virus therapeutics. Broad-Spectrum Antiviral K11777, a cysteine protease inhibitor, blocked infection when viral entry did not require activating serine proteases, as is the case with ebolavirus (EBOV). K11777 also fully inhibited coronavirus infection, but only when target cell lines lacking activating serine proteases were used. If cells expressed cell-surface serine proteases known to activate coronaviruses, both K11777 and a serine protease inhibitor, such as camostat were required for full inhibition.

* Camostat. The transmembrane serine protease, TMPRSS2 is an important target in the treatment of seasonal influenza infections and contributes to prostate carcinogenesis and metastasis. TMPRSS2 inhibition is also used in the treatment of some forms of cancer and is effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis. Recent research has found that Camostat inhibition of TMPRSS2 partially blocked infection by SARS-CoV and Human coronavirus NL63 in HeLa cells. Another in vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19. Viral spread and pathogenesis of SARS-CoV is driven by serine rather than cysteine proteases and can be effectively prevented by Camostat. Camostat has been clinically used to treat chronic pancreatitis, and thus represents an exciting potential therapeutic for respiratory coronavirus infections.

* Coronavirus Infection. Coronavirus infection symptoms depend on the type of coronavirus and how serious the infection is. If you have a mild to moderate upper-respiratory infection such as the common cold, your symptoms may include Runny nose Headache Cough Sore throat Fever Not feeling well overall Some coronaviruses can cause severe symptoms. The infections may turn into bronchitis and pneumonia, which cause symptoms such as Fever, which may be quite high if you have pneumonia Cough with mucus Shortness of breath Chest pain or tightness when you breathe and cough Severe infections are more common in people with heart or lung diseases, people with weakened immune systems, infants, and older adults. A recording based upon Malacards data on Genetic Superpathways (as of 3/27/2020).
https://www.malacards.org/card/coronavirus_infection

* Covid-19. Malacards - https://www.malacards.org/card/covid_19 -genetic pathways data as of April 2021 translated into Hz.

TLR4   IL6   IL4   IL2RA   IL1B   IFNB1
NRP1   IL6   IL4   IL2RA   IL1B   EGFR
TMPRSS2   TLR4   NRP1   IL6   IL1B   IFNB1
IL6   IL4   IL2RA   IL1B   IFNB1   IFNA2
TLR4   IL6   IL4   IL2RA   IL1B   EGFR
NRP1   IL6   IL4   IL2RA   EGFR   CCL2
TLR4   IL6   IL4   IL2RA   IFNB1   IFNA2
TLR4   IL6   IL1B   IFNB1   IFNA2   EGFR
IL6   IL4   IL2RA   IL1B   IFNA2   CXCL8
IL6   IL4   IL2RA   IFNA2   EGFR   CXCL8
IL6   IL1B   IFNB1   IFNA2   CCL2
TLR4   IL6   IL1B   IFNB1   IFNA2   F3

-TLR4 Toll Like Receptor 4 - 644.685 (Hz)
-IL6 Interleukin 6 - 434.409
-IL4 Interleukin 4 - 870.873
-IL2RA Interleukin 2 Receptor Subunit Alpha - 564.468
-IL1B Interleukin 1 Beta - 563.169
-IFNB1 Interferon Beta 1 - 408.327
-NRP1 Neuropilin 1 - 694.911
-EGFR Epidermal Growth Factor Receptor - 904.749
-TMPRSS2 Transmembrane Protease Serine 2 - 986.460
-IFNA2 Interferon Alpha 2 - 394.701
-CCL2 C-C Motif Chemokine Ligand 2 - 548.901
-CXCL8 C-X-C Motif Chemokine Ligand 8 - 552.537
-F3 Coagulation Factor III Tissue Factor - 605.661

644.685   434.409   870.873   564.468   563.169   408.327
694.911   434.409   870.873   564.468   563.169   904.749
986.460   644.685   694.911   434.409   563.169   408.327
434.409   870.873   564.468   563.169   408.327   394.701
644.685   434.409   870.873   564.468   563.169   904.749
694.911   434.409   870.873   564.468   904.749   548.901
644.685   434.409   870.873   564.468   408.327   394.701
644.685   434.409   563.169   408.327   394.701   904.749
434.409   870.873   564.468   563.169   394.701   552.537
434.409   870.873   564.468   394.701   904.749   552.537
434.409   563.169   408.327   394.701   548.901

644.685 434.409 563.169 408.327 394.701 605.661

* COVID-19 Mix

WARNING: Contains Disulfiram, do not play the mix if you -or someone else around have been drinking alcohol in the past 24h.
WARNING: Contains Arginase inhibitors, do not play the mix in the vicinity of either cats or kittens.
Each item plays for 5m.

R.- Ozonated Saline Solution
L.- Arginase Inhibitors

R.- Triazavirin, Camostat-K11777, Scutellarin
L.- Nitric Oxide-Heliox Saline, Baicalin

R.- Lapatinib, Dasatinib, Pazopanib, Sitravatinib
L.- Sildenafil, Famotidine, Fenofibrate

R.- Ubiquinone, Ezetimibe, Evolocumab
L.- Apilimod-Vacuolin-1, GC376

R.- Bamlanivimab, Etesevimab
L.- Remdesivir, Molnupiravir, DMSO, Favipiravir

R.- Niclosamide, Proxalutamide, Tocilizumab, Budesonide
L.- Lopinavir, Ritonavir

R.- Evans blue, Lumacaftor, Sodium Lifitegrast
L.- Ivermectin, Disulfiram, Azithromycin

R.- Casirivimab
L.- Imdevimab

R.- Hesperetin, Nicotinamide, Glycyrrhizin
L.- Vitamin B12, Vitamin A, Zinc, Magnesium

* diABZI Sting Agonists. The drug diABZI—which activates the body's innate immune response—was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2. The findings suggest that diABZI could also treat other respiratory coronaviruses. The researchers found that diABZI potently inhibits SARS-CoV-2 infection of diverse strains, including variant of concern B.1.351, by stimulating interferon signaling. diABZI could be an effective treatment for SARS-CoV-2 that could prevent severe COVID-19 symptoms and the spread of infection. Additionally, since diABZI has been shown to inhibit human parainfluenza virus and rhinovirus replication in cultured cells, the STING agonist may be more broadly effective against other respiratory viruses.

* EpiVacCorona Vaccine is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides (short fragments of a viral spike protein) that are conjugated to a large carrier protein. The vaccine is delivered via intramuscular route and aluminum hydroxide serves as an immunological adjuvant.

* Gastroenteritis. Gastroenteritis is a gastrointestinal system infectious disease that involves inflammation of the lining of the stomach and small and large intestines, which is caused by viruses, bacteria, or parasites. Chemicals and drugs also cause gastroenteritis. The symptoms include diarrhea, loss of appetite, nausea, vomiting, cramps, and discomfort in the abdomen. A recording based upon Malacards data on Genetic Superpathways (as of 3/28/2020).
https://www.malacards.org/card/gastroenteritis

* Hydroxychloroquine is used to treat systemic lupus erythematosus, rheumatic disorders like rheumatoid arthritis, porphyria cutanea tarda, and Q fever, and certain types of malaria. It is considered the first line treatment for systemic lupus erythematosus. Certain types of malaria, resistant strains, and complicated cases require different or additional medication. Hydroxychloroquine is being studied as an experimental treatment for coronavirus disease 2019 (COVID-19). Azithromycin is an antibiotic used for the treatment of a number of bacterial infections. This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and certain other intestinal infections. It can also be used for a number of sexually transmitted infections, including chlamydia and gonorrhea infections. Along with other medications, it may also be used for malaria. A new controlled clinical study conducted by doctors in France shows that a combo of Hydroxychloroquine and Azithromycin (Z-Pak) cures 100% of coronavirus patients within 6 days of treatment.

* Lufotrelvir (PF-07304814) is the phosphate prodrug of PF-00835231, an anticoronaviral agent. It has a role as a prodrug, an EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor and an anticoronaviral agent. The protease 3CLpro is a potential drug target for coronavirus infections due to its essential role in processing the polyproteins that are translated from the viral RNA. The X-ray structures of the unliganded SARS-CoV-2 protease 3CLpro and its complex with an α-ketoamide inhibitor provides a basis for design of α-ketoamide inhibitors for a treatment of SARS-CoV-2 infection. The intravenous administered prodrug PF-07304814 entered clinical trials in September 2020, and the orally-active follow-up drug PF-07321332 started recruiting patients in February 2021. Lufotrelvir (PF-07304814) is a potential novel treatment option for hospitalized patients. PF-07321332 is designed as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care. Together, the two have the potential to solve the treatment paradigm that complements vaccination in cases where disease still occurs.

* Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication. On 1 October 2021, Merck stated that an independent advisory board that had been monitoring the COVID-19 clinical trial recommended that recruitment into the study be stopped early because of convincing evidence of the drug's benefits, reducing the risk of hospitalization or death by 48%. Merck announced plans to seek an EUA from the FDA, and to submit marketing applications to other global drug regulators. The company announced plans to license the drug to generic manufacturers, to accelerate its availability.

* Paxlovid or PF-07321332 is an inhibitor of SARS-CoV-2 main protease which is currently under clinical development for the treatment of COVID-19. It has a role as an EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor and an anticoronaviral agent. It is a nitrile, a member of pyrrolidin-2-ones, a secondary carboxamide, a pyrrolidinecarboxamide, a tertiary carboxamide, an organofluorine compound and an azabicyclohexane. The intravenous administered prodrug PF-07304814 entered clinical trials in September 2020, and the orally-active follow-up drug PF-07321332 started recruiting patients in February 2021. PF-07321332 is designed as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care. At the same time, Lufotrelvir (PF-07304814) is a potential novel treatment option for hospitalized patients. Together, the two have the potential to solve the treatment paradigm that complements vaccination in cases where disease still occurs. Paxlovid is an antiviral drug which acts as an orally active 3CL protease inhibitor. It is a covalent inhibitor, binding directly to the catalytic cysteine (Cys145) residue of the enzyme. Paxlovid is in phase 3 trials for the treatment of COVID-19 in combination with ritonavir. In November 2021, Pfizer announced positive phase 2/3 results, including 89% reduction in hospitalizations when given within three days after symptom onset.

* Severe Acute Respiratory Syndrome. Severe Acute Respiratory Syndrome is a Coronavirus infection that results in infection located in respiratory tract, has material basis in SARS coronavirus (SARS-CoV), which is transmitted by droplet spread of respiratory secretions, transmitted by ingestion of contaminated food, or transmitted by fomites. The infection has symptom fever, has symptom headache, has symptom body aches, has symptom dry cough, and has symptom hypoxia. A recording based upon Malacards data on Genetic Superpathways (as of 3/27/2020).
https://www.malacards.org/card/severe_acute_respiratory_syndrome

* Viral Infectious Disease. A viral disease (or viral infection, or infectious disease) occurs when an organism's body is invaded by pathogenic viruses, and infectious virus particles (virions) attach to and enter susceptible cells. A recording based upon Malacards data on Genetic Superpathways (as of 3/31/2020).
https://www.malacards.org/card/viral_infectious_disease

* Viral Pneumonia. A pneumonia is described as an inflammatory illness of the lung commonly caused by viruses such as influenza virus, parainfluenza, adenovirus, rhinovirus, herpes simplex virus, respiratory syncytial virus, hantavirus, and cytomegalovirus. A recording based upon Malacards data on Genetic Superpathways (as of 3/27/2020).
https://www.malacards.org/card/viral_pneumonia